Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Fox Chase BR-076: Pembrolizumab in TNBC - Clinical Trial

What is the Purpose of this Study?

We are doing this study is to see if the study drug, pembrolizumab, plus chemotherapy (carboplatin and gemcitabine) is safe and effective in treating people with metastatic triple negative breast cancer.
What is the Condition Being Studied?
Triple Negative Metastatic Breast Cancer

Who Can Participate in the Study?

Adult women who :
- Have metastatic, triple negative breast cancer (spread to other parts of your body).
- Have already received up to 2 cancer therapies for their metastatic breast cancer
- Are candidates for chemotherapy with carboplatin and gemcitabine.

Age Group
Adults

What is Involved?

If you join this study, you will be randomly put into a study group, like drawing numbers out of a hat.

- If you are in group 1, you will get pembrolizumab along with chemotherapy (carboplatin and gemcitabine).
- If you are in group 2, you will receive chemotherapy (carboplatin and gemcitabine) alone.

- You will have tests, exams, and procedures that are part of your standard of care and for study purposes.
- You will be asked to take the study drugs for up to 2 years. You will be followed until the study ends.

Study Details

Full Title
A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00086335
NCT: NCT02755272
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698